Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986371 (Gamcemetinib) DDI with Methotrexate and Sulfasalazine
NCT05445440Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gamcemetinib in ankylosing spondylitis (AS) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration up to 22 days, Area under the plasma concentration-time curve from time zero extrapolated to infinite time up to 22 days and 1 more. Started Sep 2022; status: completed.
02
Drugs
gamcemetinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05445440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445440.